These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 34851157)

  • 1. Dose Optimization of Combined Linezolid and Fosfomycin against
    Mao J; Li T; Zhang N; Wang S; Li Y; Peng Y; Liu H; Yang G; Yan Y; Jiang L; Liu Y; Li J; Huang X
    Microbiol Spectr; 2021 Dec; 9(3):e0087121. PubMed ID: 34851157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose Optimization of Colistin Combinations against Carbapenem-Resistant Acinetobacter baumannii from Patients with Hospital-Acquired Pneumonia in China by Using an
    Bian X; Liu X; Chen Y; Chen D; Li J; Zhang J
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activities of daptomycin combined with fosfomycin or rifampin on planktonic and adherent linezolid-resistant isolates of Enterococcus faecalis.
    Zheng JX; Sun X; Lin ZW; Qi GB; Tu HP; Wu Y; Jiang SB; Chen Z; Deng QW; Qu D; Yu ZJ
    J Med Microbiol; 2019 Mar; 68(3):493-502. PubMed ID: 30882300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developments in the pharmacokinetic/pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients.
    Dong H; Xie J; Chen L; Wang T; Sun J; Zhao Y; Dong Y
    Int J Infect Dis; 2014 May; 22():35-40. PubMed ID: 24603161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics of Linezolid Plus Fosfomycin Against Vancomycin-Resistant
    Wang S; Liu H; Mao J; Peng Y; Yan Y; Li Y; Zhang N; Jiang L; Liu Y; Li J; Huang X
    Front Microbiol; 2021; 12():779885. PubMed ID: 34970238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic properties of linezolid against Enterococcus spp. isolates: a systematic review from in vitro studies.
    Antonello RM; Riccardi N; Saderi L; Sotgiu G
    Eur J Clin Microbiol Infect Dis; 2024 Jan; 43(1):17-31. PubMed ID: 37975976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the Emergence of Resistance in vitro and Invivo: Linezolid Combined with Fosfomycin Against Fosfomycin-Sensitive and Resistant
    Li Y; Peng Y; Zhang N; Liu H; Mao J; Yan Y; Wang S; Yang G; Liu Y; Li J; Huang X
    Infect Drug Resist; 2022; 15():4995-5010. PubMed ID: 36065277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment options for vancomycin-resistant enterococcal infections.
    Linden PK
    Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study on combination of daptomycin with selected antimicrobial agents: in vitro synergistic effect of MIC value of 1 mg/L against MRSA strains.
    Lee YC; Chen PY; Wang JT; Chang SC
    BMC Pharmacol Toxicol; 2019 May; 20(1):25. PubMed ID: 31060599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriaceae in in vitro pharmacokinetic/pharmacodynamic model experiments.
    Albur MS; Noel A; Bowker K; MacGowan A
    Int J Antimicrob Agents; 2015 Nov; 46(5):560-7. PubMed ID: 26387065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro efficacy of fosfomycin-based combinations against clinical vancomycin-resistant Enterococcus isolates.
    Tang HJ; Chen CC; Zhang CC; Su BA; Li CM; Weng TC; Chiang SR; Ko WC; Chuang YC
    Diagn Microbiol Infect Dis; 2013 Nov; 77(3):254-7. PubMed ID: 24029433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activities of fosfomycin and rifampin on planktonic and adherent Enterococcus faecalis strains in an experimental foreign-body infection model.
    Oliva A; Furustrand Tafin U; Maiolo EM; Jeddari S; Bétrisey B; Trampuz A
    Antimicrob Agents Chemother; 2014; 58(3):1284-93. PubMed ID: 24145537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral Fosfomycin Treatment for Enterococcal Urinary Tract Infections in a Dynamic
    Abbott IJ; van Gorp E; van der Meijden A; Wijma RA; Meletiadis J; Roberts JA; Mouton JW; Peleg AY
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32253214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic activity of fosfomycin and chloramphenicol against vancomycin-resistant Enterococcus faecium (VREfm) isolates from bloodstream infections.
    Lagatolla C; Milic J; Imperi F; Cervoni M; Bressan R; Luzzati R; Di Bella S
    Diagn Microbiol Infect Dis; 2021 Feb; 99(2):115241. PubMed ID: 33130503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an In Vitro Infection Model.
    VanScoy BD; McCauley J; Ellis-Grosse EJ; Okusanya OO; Bhavnani SM; Forrest A; Ambrose PG
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7170-7. PubMed ID: 26100706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase.
    Albiero J; Mazucheli J; Barros JPDR; Szczerepa MMDA; Nishiyama SAB; Carrara-Marroni FE; Sy S; Fidler M; Sy SKB; Tognim MCB
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model.
    Boak LM; Li J; Rayner CR; Nation RL
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1287-92. PubMed ID: 17242144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elucidation of the pharmacokinetic/pharmacodynamic determinants of fosfomycin activity against Pseudomonas aeruginosa using a dynamic in vitro model.
    Bilal H; Peleg AY; McIntosh MP; Styles IK; Hirsch EB; Landersdorfer CB; Bergen PJ
    J Antimicrob Chemother; 2018 Jun; 73(6):1570-1578. PubMed ID: 29506207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concentration-dependent enrichment of resistant Enterococcus faecium exposed to linezolid in an in vitro dynamic model.
    Alieva KN; Golikova MV; Portnoy YA; Dovzhenko SA; Kobrin MB; Zinner SH; Firsov AA
    J Chemother; 2018; 30(6-8):364-370. PubMed ID: 30663551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vitro and In Vivo Activities of a Bi-Aryl Oxazolidinone, RBx 11760, against Gram-Positive Bacteria.
    Barman TK; Kumar M; Mathur T; Chaira T; Ramkumar G; Kalia V; Rao M; Pandya M; Yadav AS; Das B; Upadhyay DJ; Hamidullah ; Konwar R; Raj VS; Singh H
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7134-7145. PubMed ID: 27645240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.